Product Information
Registration Status: ActiveSIN08681P
SELEGOS TABLET 5mg is approved to be sold in Singapore with effective from 1996-04-30. It is marketed by MEDOCHEMIE SINGAPORE PTE LTD, with the registration number of SIN08681P.
This product contains Selegiline 5mg in the form of TABLET. It is approved for ORAL use.
This product is manufactured by MEDOCHEMIE LTD in CYPRUS.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
Indication
Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.
Mechanism of Action
Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the selective, irreversible inhibition of monoamine oxidase type B (MAO-B) is thought to be of primary importance. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantial nigra. Selegiline may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, selegiline can also inhibit monozmine oxidase type A (MAO-A), allowing it to be used for the treatment of depression.
Pharmacokinetics
- Absorption
- Rapidly absorbed from the gastrointestinal tract.
- Distribution
- Metabolism
- Elimination
Toxicity
LD50=63 mg/kg (rats, IV)
Active Ingredient/Synonyms
(−)-selegiline | L-Deprenalin | Selegilina | Selegilinum | Selegiline |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.